Blood

Vol. 147, Issue 7 Issue 7 2026
11
Articles

Articles in this Issue

Integrin αvβ8–mediated TGF-β1 activation regulates the sustained response in immune thrombocytopenia after TPO-RA withdrawal

Heng Mei, Min Xu, Jinhui Shu et al. Feb 12, 2026 pp. 783-799 10.1182/blood.2025029769

Abstract Only 30% to 50% of patients with immune thrombocytopenia (ITP) exhibit a sustained response upon thrombopoietin receptor agonists (TPO-RA) withdrawal, underscoring the nec...

MMF unlocks a new path to venetoclax sensitivity in AML

Daisuke Nakada Feb 12, 2026 pp. 708-709 10.1182/blood.2025032116

Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells

Gentaro Kawano, Riichiro Ikeda, Daisuke Ishihara et al. Feb 12, 2026 pp. 768-782 10.1182/blood.2025030209

Abstract Therapy resistance in acute myeloid leukemia (AML) remains a major clinical obstacle, particularly because of the persistence of leukemia stem cells (LSC) capable of metab...

Prostaglandins in cancer revisited: principles of production, mechanisms of immune regulation, and therapeutic perspectives

Erik Müller, Bastian Kruse, Jan P. Böttcher Feb 12, 2026 pp. 713-724 10.1182/blood.2025029806

Abstract The cyclooxygenase (COX) signaling pathway is frequently dysregulated in cancer, resulting in the aberrant production of prostaglandins, a distinct class of bioactive lipi...

Follicular lymphoma transformed to classic Hodgkin lymphoma

Leonard Nsoyori Yenwongfai, Ivo M. B. Francischetti Feb 12, 2026 pp. 800-800 10.1182/blood.2025031906

The ticking clock of relapse in T-cell lymphomas

Qu Jiang, Marco Herling Feb 12, 2026 pp. 707-708 10.1182/blood.2025032024

Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia

Brett Schroeder, Constance Yuan, Hao-Wei Wang et al. Feb 12, 2026 pp. 725-738 10.1182/blood.2025031243

Abstract The primary objective in multiply relapsed hairy cell leukemia and variant (HCL/HCLv) was to determine whether pentostatin-rituximab (DCFR) and bendamustine-rituximab (BR)...

An old but still good friend: chemoimmunotherapy in HCL

Enrico Tiacci, Alessandro Mancini Feb 12, 2026 pp. 705-707 10.1182/blood.2025031748

Inflammation perturbs hematopoiesis by remodeling specific compartments of the bone marrow niche

James W. Swann, Ruiyuan Zhang, Evgenia V. Verovskaya et al. Feb 12, 2026 pp. 739-754 10.1182/blood.2025029513

Abstract Hematopoietic stem and progenitor cells are regulated by interactions with stromal cells in the bone marrow (BM) cavity, which can be segregated into 2 spatially defined c...

Stuck on you: Tregs, αvβ8, TGF-β1, and platelets in ITP

Margaret V. Ragni Feb 12, 2026 pp. 709-711 10.1182/blood.2025031893

Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium

Mark N. Sorial, Luis E. Malpica Castillo, Carlos Chiattone et al. Feb 12, 2026 pp. 755-767 10.1182/blood.2025030149

abstract We assessed the overall survival (OS) impact of time to relapse (TTR) in multinational cohorts with independent observational and randomized validation. Patients with nMTC...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page